Comparison of Standard Versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialysis Patients: a Randomized Controlled Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

January 4, 2025

Study Completion Date

January 27, 2025

Conditions
HemodialysisThrombolytic TherapyDialysis Access DysfunctionRandomised Controlled TrialEnd Stage Renal Disease (ESRD)
Interventions
DRUG

Urokinase

In the higher dose group: 30,000unit (1.5ml) per catheter lumen is instilled per catheter lumen (in both arterial and venous ports respectively). This allows utilization of the entire vial of Urokinase to prevent wastage and to assess if this increase in dose improves catheter patency and survival, thus reducing the need for a TDC exchange in our HD patients. The urokinase lock is dwelled for at least 2 hours, after which aspiration and catheter testing will be done by a trained HD nurse.

DRUG

Urokinase

20,000unit (1ml) is instilled per catheter lumen (in both arterial and venous ports respectively); and the remaining 1ml is discarded.

Trial Locations (1)

768828

Khoo Teck Puat Hospital, Singapore

All Listed Sponsors
lead

National Healthcare Group, Singapore

OTHER_GOV

NCT06802679 - Comparison of Standard Versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialysis Patients: a Randomized Controlled Trial | Biotech Hunter | Biotech Hunter